Contents
Clinical research in Vermont is here to test the safety and efficacy of new interventions, drugs, and therapies. Volunteers make treatment discoveries possible. By diversifying the clinical trials, experts can improve patient care for all kinds of diseases.
Be the missing piece in medical breakthrough. We are here to help you enlist for a clinical trial.
Clinical Trials For Disease Areas in Vermont
There are over 1,000 active clinical research trials in Vermont across different specialty areas. Every research opportunity provides more data that can help prevent, diagnose, or treat a disease.
Some of the most notable disease areas studied in Vermont are psychiatric diseases, antibiotic resistance, metabolic disorders, respiratory diseases, musculoskeletal conditions, and neurological complications.
Recently, scientists at the University of Vermont received a $450,000 grant to continue their research. The clinical study could eventually find a novel approach to treat rare, more aggressive forms of breast cancer.
Your contribution is equally valuable. Volunteer for a clinical trial and help shape the treatments of tomorrow. Browse the list below for active and future trials.
Generic Database of Very Low Birth Weight Infants
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials. Read Less
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Vermont, Burlington, Vermont
University of Vermont, Burlington, Vermont
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Burlington, Vermont
Not set, Burlington, Vermont
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: University of Vermont and State Agricultural College, Burlington, Vermont
University of Vermont and State Agricultural College, Burlington, Vermont
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Read Less
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: University of Vermont and State Agricultural College, Burlington, Vermont
University of Vermont and State Agricultural College, Burlington, Vermont
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Product Surveillance Registry
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/24/2025
Locations: Not set, Burlington, Vermont
Not set, Burlington, Vermont
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Recruiting
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: University of Vermont, Burlington, Vermont
University of Vermont, Burlington, Vermont
Conditions: Huntington's Disease
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Recruiting
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
05/22/2025
Locations: University of Vermont and State Agricultural College, Burlington, Vermont
University of Vermont and State Agricultural College, Burlington, Vermont
Conditions: Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Recruiting
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, wor... Read More
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: Dartmouth Cancer Center - North, Saint Johnsbury, Vermont
Dartmouth Cancer Center - North, Saint Johnsbury, Vermont
Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Vermont Oxford Network Very Low Birth Weight Database
Recruiting
Vermont Oxford Network maintains a database for live born infants \<=1500 grams or \<=29 weeks gestational age who are born at participating hospitals or admitted to them within 28 days of birth, regardless of where in the hospital the infant receives care.
Vermont Oxford Network maintains a database for live born infants \<=1500 grams or \<=29 weeks gestational age who are born at participating hospitals or admitted to them within 28 days of birth, regardless of where in the hospital the infant receives care. Read Less
Gender:
ALL
Ages:
28 days and below
Trial Updated:
11/19/2024
Locations: Vermont Oxford Network, Burlington, Vermont
Vermont Oxford Network, Burlington, Vermont
Conditions: Neonatology
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Recruiting
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marke... Read More
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: University of Vermont, Burlington, Vermont
University of Vermont, Burlington, Vermont
Conditions: Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma, Brain Tumors, Brain Cancer
Paid Clinical Trials in Vermont
By participating in paid clinical trials in Vermont, you get immediate access to treatments that are not available anywhere else. Not only that, but you also receive compensation for your services.
You can get paid, or get other benefits. Such as free medical treatment, covered travel and food expenses, vouchers, etc. Check the details of VT paid clinical trials before applying.
Clinical Trials For Health Volunteers in Vermont
Clinical trials are the safest and fastest ways to find treatments that work. Each trial uses healthy or sick volunteers to answer scientific questions.
But, before a new drug becomes available to the public, research teams in Vermont need to test it to see if it works. With your help, they can make the latest treatments a reality.
Seize the opportunity to shape the future of medicine. Apply for a clinical trial now.
Integrated Cancer Repository for Cancer Research
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies. Read Less
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: Rutland Regional Medical Center, Rutland, Vermont
Rutland Regional Medical Center, Rutland, Vermont
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Avocado and Postprandial Responses
Recruiting
The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating.
The investigators will test the effects of 3 breakfast meals on blood sugar control and signals of hunger and fullness after eating:
1. Whole-wheat bread and strawberry jam
2. Whole-wheat bread, strawberry jam, and avocado
3. Whole-wheat bread and strawberry jam (meal enriched with fat and fiber to mimic that of an avocado)
Participants will u... Read More
The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating.
The investigators will test the effects of 3 breakfast meals on blood sugar control and signals of hunger and fullness after eating:
1. Whole-wheat bread and strawberry jam
2. Whole-wheat bread, strawberry jam, and avocado
3. Whole-wheat bread and strawberry jam (meal enriched with fat and fiber to mimic that of an avocado)
Participants will undergo 3 test periods, each separated by a week. Each test period consists of one day with set meals that the investigators will provide (breakfast, lunch, and dinner), and then the next morning, participants will eat a breakfast meal and have blood drawn several times over 4 hours. Read Less
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/24/2025
Locations: Clinical Research Center, University of Vermont Medical Center, Burlington, Vermont
Clinical Research Center, University of Vermont Medical Center, Burlington, Vermont
Conditions: Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
Medical Discoveries and Innovation in Vermont
While Vermont may not have been the epicenter of medical innovation on a global scale, it does have a fair share of notable contributions. Here are some of the medical achievements that helped shape the field of medicine.
- Mental Health Advocacy – Vermont is at the forefront of promoting mental health and addiction recovery. Many educates, advocates and support programs have helped patients get access to adequate mental health treatment so that they can build better lives.
- Genetic Research – The University of Vermont provides valuable data for genetic studies. That includes studies on genetic diseases and personalized medicine.
- Prosthetic Technology – Experts and engineering students are a valuable component of the early development of artificial limbs. They are using 3D printers in Vermont clinical research to create and test custom-fitted prosthetics. These prosthetics are more affordable to the general public.
Why Vermont Is A Great Place For Clinical Research
Minorities are underrepresented in clinical trials. Vermont is a good place for clinical research because it helps diversify the pool of volunteers. Although 92.2% of its residents are White, there are other minorities who live here. About 2.2% are Hispanic, 2% are Asian, 1.9% are Multiracial, 1.3% are Black, and 0.3% are American Indian.